SynAct Pharma secures key US patent
SynAct Pharma has been granted a pivotal US patent protecting the crystal form of resomelagon, a drug candidate currently in phase IIb clinical development for rheumatoid arthritis.
SynAct Pharma is a clinical stage biotechnology company focused on developing treatments for inflammatory diseases. The company’ candidate resomelagon (AP1189) selectively stimulates melanocortin receptors, intended to help the body resolve inflammation.
During the development of resomelagon, SynAct Pharma identified a crystal form of this salt with beneficial properties. SynAct Pharma recently announced that the United States Patent and Trademark Office (USPTO) has issued a patent with claims covering the crystal form of resomelagon. The patent approval ensures exclusive rights to resomelagon’s composition of matter in the US until 2042.
In a press release, SynAct Pharma’s Chief Operating Officer, Thomas Boesen, highlighted the significance of the patent, emphasizing its broad protection regardless of formulation or use.
“We are thrilled by this news which supports that we have laid out a successful patent strategy for resomelagon. A composition of matter patent for a crystal form of a drug candidate will apply irrespective of how the claimed solid is formulated or used, and thus it is a very broad and strong patent.”
Extended exclusive rights
CEO Jeppe Øvlesen further stated that securing patent coverage in the US enhances the drug’s commercial potential and attractiveness to partners:
“To obtain patent coverage of resomelagon as composition of matter in a major market like the US is very important for us, our potential partners and the future value of developing AP1189 as a drug.”
The patent extends SynAct Pharma’s exclusive rights for resomelagon by several years beyond projected market entry.
SynAct Pharma is currently conducting a phase IIb study (ADVANCE) with resomelagon in Europe and the US to validate its treatment potential for rheumatoid arthritis. The company aims to enroll all 240 patients by Q4 2025. If the study yields positive results, the next step will be to advance to phase III development.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
